May 11, 2022 / 07:00PM GMT
Gregory Allen Harrison - BofA Securities, Research Division - Analyst
(technical difficulty) of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. And it's my pleasure today to introduce Mark McClung, Executive Vice President and CEO of Sangamo Therapeutics.
Mark, would you like to give some opening remarks. And then after that, we can jump into the Q&A?
D. Mark McClung - Sangamo Therapeutics, Inc. - Executive VP & COO
Yes, absolutely. So first of all, Greg, Mary Kate, thanks for having us, and thank you for your interest in Sangamo Therapeutics. So these are forward-looking statements. And as usual, we refer you to the quarterly filing that was put in last week, just for your reference.
So Sangamo Therapeutics is an exciting company. Actually, it's a genomics medicine company. It's got a long history in terms of being a pioneer in genomic medicines that hopefully will give you a sense of today. We've got multiple
Sangamo Therapeutics Inc at Bank of America Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers